A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of
MGL-3196 as compared with placebo resolves NASH on liver biopsy and prevents progression to
cirrhosis and/or advanced liver disease